Published in final edited form as:

ACS Chem Biol. 2011 March 18; 6(3): 218–222. doi:10.1021/cb1002762.

Identification of SR3335 (ML176): a Synthetic ROR α Selective Inverse Agonist

Naresh Kumar, Douglas J. Kojetin, Laura A. Solt, K. Ganesh Kumar, Philippe Nuhant, Derek R. Duckett, Michael D. Cameron, Andrew A. Butler, William R. Roush, Patrick R. Griffin^{*}, and Thomas P. Burris^{*}

The Scripps Research Institute, Jupiter, FL 33458

Abstract

Several nuclear receptors (NRs) are still characterized as orphan receptors since ligands have not yet been identified for these proteins. The retinoic acid receptor-related receptors (RORs) have no well-defined physiological ligands. Here, we describe the identification of a selective ROR α synthetic ligand, SR3335 (ML-176). SR3335 directly binds to ROR α , but not other RORs, and functions as a selective partial inverse agonist of ROR α in cell-based assays. Furthermore, SR3335 suppresses the expression of endogenous ROR α target genes in HepG2 involved in hepatic gluconeogenesis including *glucose-6-phosphatase* and *phosphoenolpyruvate carboxykinase*. Pharmacokinetic studies indicate that SR3335 displays reasonable exposure following an i.p. injection into mice. We assess the ability of SR3335 to suppress gluconeogenesis *in vivo* using a diet induced obesity (DIO) mouse model where the mice were treated with 15 mg/kg b.i.d., i.p. for 6-days followed by a pyruvate tolerance test. SR3335 treated mice displayed lower plasma glucose levels following the pyruvate challenge consistent with suppression of gluconeogenesis. Thus, we have identified the first selective synthetic ROR α inverse agonist and this compound can be utilized as a chemical tool to probe the function of this receptor both *in vitro* and *in vivo*. Additionally, our data suggests that ROR α inverse agonists may hold utility for suppression of elevated hepatic glucose production in type 2 diabetics.

Several nuclear receptors (NRs) are still characterized as orphan receptors since ligands have not yet been identified for these proteins. NRs display a conserved domain structure with highly conserved DNA-binding and ligand-binding domains. The retinoic acid receptor-related orphan receptor α (ROR α) is an orphan receptor that has been demonstrated to play an important role in regulation of metabolism (1,2). Cholesterol and its sulfate derivative have been suggested to be natural ligands for ROR α (3,4). More recently, our work identified various oxygenated sterols that bind to both ROR α and ROR γ with high affinity and regulate their activity (5,6). The RORs have been characterized as constitutively active receptors displaying the ability to activate transcription in the absence of a ligand; however, there is some controversy as to the nature of this constitutive activity. Our data indicate that RORs display the constitutive activity in biochemical assays under conditions where the receptor would be expected to have no ligand present (denatured and refolded receptor) (5), but others have suggested that endogenous ligands may copurify with the receptor leading to this activity (7). Although the physiological significance of these natural ligands for the RORs is unclear, the potential utility of synthetic ligands that modulate the activity of these receptors is apparent. For example, loss of ROR α in the *staggerer* mice results in mice resistant to weight gain and hepatic steatosis when placed on a high fat diet

^{*}Correspondence: Thomas P. Burris, Ph.D. or Patrick R. Griffin, Ph.D., The Scripps Research Institute, Jupiter, FL 33458, tburris@scripps.edu or pgriffin@scripps.edu.

suggesting that suppression of ROR α activity may offer efficacy in treatment of obesity(8). ROR α has also been shown to be a critical factor regulating the expression of key enzymes in the gluconeogenic pathway (9) and suppression of ROR α activity may lead to suppression of elevated hepatic glucose output that is observed in type 2 diabetics.

We recently identified the first synthetic ligand that binds to and regulates the activity of ROR α and ROR γ , T0901317 (T1317) (Fig. 1A) (10). T1317 was originally identified as a liver X receptor agonist (LXR) (11), an NR that serves as a physiological receptor for oxysterols and plays key roles in regulation of lipogenesis and reverse cholesterol transport (12). Our group demonstrated that T1317 displays a degree of promiscuity and also activated another NR that serves as a receptor for bile acids, FXR (13). Interestingly, T1317 acts as a LXR agonist, but a ROR inverse agonist. We utilized the benzenesulfonamide scaffold as an initiation point for development of the first selective ROR ligand, SR1078 that behaves as a dual ROR α/γ agonist (14).

Continued evaluation of this scaffold led to the identification of a ROR α selective inverse agonist that is characterized in this study, SR3335 (ML-176) (Fig. 1A). The synthetic scheme for SR3335 is shown in Fig. 1B. This compound was initially identified based on its ability to inhibit the constitutive activity of ROR α in a GAL4-ROR α ligand binding domain (LBD) cotransfection assay. In a biochemical radioligand binding assay using [3 H]25-hydroxycholesterol as a label (5,6,10) it is clear that unlabeled SR3335 dose-dependently competes for binding to the ROR α LBD (Fig. 1C). The K_i was calculated as 220 nM using the Cheng-Prusoff equation. As shown in Fig. 1D, SR3335 did not compete well for binding when the LBD of ROR γ was utilized. In a cell-based chimeric receptor Gal4 DNA-binding domain – NR ligand binding domain cotransfection assay, SR3335 significantly inhibited the constitutive transactivation activity of ROR α (IC_{50} =480 nM)(partial inverse agonist activity), but had no effect on the activity of LXR α and ROR γ (Fig. 2). Although T1317 shows considerably more efficacy than SR3335 in terms of suppression of ROR α activity, the ROR α selectivity of SR3335 is clear. SR3335 also displays no activity on ROR β (radioligand binding or cotransfection assays), FXR (cotransfection assays) or any other receptors in a selectivity panel for human nuclear receptors (10) (data not shown). We also observed no effect on the enzymatic activity of kinases (JNK or MAPK). These data clearly demonstrate that we developed a compound that selectively targets ROR α .

In order to examine the activity of SR3335 in more detail, we performed additional cotransfection assays where we transfected cells with full-length ROR α and a luciferase reporter gene driven by a promoter derived from a known ROR target gene, *glucose-6-phosphatase (G6Pase)*. *G6Pase* is a well-characterized ROR α target gene that plays a critical role in the gluconeogenesis pathway (5,9,15). As shown in Fig. 3A, in a ROR α cotransfection assay, treatment of cells with SR3335 resulted in a significant suppression of transcription driven by the *G6Pase* promoter. Consistent with these cotransfection data, treatment of HepG2 cells with SR3335 lead to suppression of expression of both *G6Pase* and *phosphoenolpyruvate carboxykinase (PEPCK)* mRNA expression (Fig. 3B). Given the critical roles that these two enzymes play in regulation of gluconeogenesis, we hypothesized that SR3335 may offer utility in suppression of hepatic glucose output, which is elevated in type 2 diabetics and contributes to the hyperglycemic state. In order to investigate this, we pursued additional studies in mice.

We examined the pharmacokinetic properties of SR3335 in mice and noted significant *in vivo* exposure. Plasma concentrations reached nearly 9 μ M 0.5h after a 10 mg/kg i.p. injection of SR3335 and levels were sustained above 360 nM even 4h after the single injection (Fig. 4A). These levels were sufficient to perform a proof-of-principle experiment to determine if SR3335 treatment could suppress gluconeogenesis *in vivo*. Diet induced

obese mice were treated with SR3335 (15 mg/kg b.i.d., i.p.) for 6-days and a pyruvate tolerance test was performed on day 6 to estimate gluconeogenesis. As shown in Fig. 4B plasma glucose levels were slightly lower in SR3335 treated animals at time 0, but after injection of the pyruvate the SR3335 treated animals displayed significantly lower plasma glucose levels at each time point vs. vehicle treated animals (15, 30, and 60 min) indicating suppression of hepatic gluconeogenesis and an improvement in glucose homeostasis by the ROR α inverse agonist. Expression of hepatic *pepck* and *g6pase* expression in the mice revealed ~50% decrease in *pepck* expression (the enzyme that catalyzes the rate limiting step in gluconeogenesis); however, *g6pase* expression was not significantly affected (Fig. 4C). It is unclear why only *pepck* expression was suppressed *in vivo* and not *g6pase* since both were repressed in cell culture experiments, but the suppression of only *pepck* *in vivo* may be responsible for the moderate effects on pyruvate stimulated gluconeogenesis. Clearly SR3335 is effectively targeting ROR α since a well characterized ROR α target gene (*nr1d1*) (16,17) is also repressed in the livers (Fig. 4C). Importantly, mice treated with SR3335 displayed no difference in body weight or food intake after 7-days of treatment with the compound (data not shown). The effects on glucose homeostasis are thus not secondary to weight loss and represent a metabolic response to the compound.

Several crystal structures of the LBD of both ROR α and ROR γ bound to sterol ligands have been solved (3,4,7). In all of these cases the LBD appears to be in an active conformation with helix 12 positioned in such a manner to allow for coactivator protein recruitment. It is unclear whether binding of a sterol is required for the transcriptional activity of these receptors since we have clearly observed that ROR α and ROR γ expressed in a sterol free environment retain constitutive ability to recruit coactivators (5,10). We do observe that SR3335 is able to displace 25-hydroxycholesterol in a radioligand binding assay, thus whether it be by displacing an endogenous agonist or by binding to a receptor that has a basal conformation that is already active, SR3335 appears to limit the receptor's ability to activate transcription. This is most likely due to SR3335 inducing a conformation that reduces the affinity of the LBD for coactivators.

In summary, we report the identification of the first selective synthetic ROR α ligand that functions as an inverse agonist. In cotransfection assays, SR3335 suppresses transcription in both GAL4-ROR α LBD and full-length ROR α contexts. Furthermore, treatment of HepG2 cells with SR3335 results in suppression of ROR α target gene expression. Suppression of the expression of *G6Pase* and *PEPCK* mRNA suggested that SR3335 might be able to suppress gluconeogenesis. After determining that SR3335 displayed reasonable pharmacokinetics in mice, we tested this hypothesis and *in vivo* using a DIO mouse model and showed that SR3335 did indeed suppress gluconeogenesis. These data clearly define SR3335 as a valid chemical tool to evaluate the *in vitro* and *in vivo* actions of ROR α and suggest that compounds like SR3335 may hold utility in treatment of type 2 diabetes.

Methods

Synthesis of SR3335

To a solution of 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (18) (1.5M in THF, 2.90 mL, 4.35 mmol) in acetone (4.3 mL) were successively added at room temperature 2,6-lutidine (658 μ L, 5.65 mmol) and 2-thiophenesulfonyl chloride (910 mg 4.78 mmol). The mixture was heated overnight at 60°C, then diluted by ethyl acetate (EtOAc) and quenched at room temperature by the addition of saturated NaHCO₃ solution. The aqueous phase was extracted two times with EtOAc. The combined organic phases were dried over Na₂SO₄, filtrated and concentrated on a rotary evaporator. The residue was purified by silica gel column and eluted with hexane-EtOAc (70/30) to obtain 1.1 g of SR3335 (62%, purity >98%) as a white powder: ¹H NMR (400 MHz, (CD₃)₂SO) δ 6.64 (dd, *J* = 5.0, 3.8 Hz, 1H),

6.77 (d, $J = 8.8$ Hz, 2H), 7.08 (d, $J = 8.8$ Hz, 2H), 7.14 (dd, $J = 3.7, 1.4$ Hz, 1H), 7.43 (d, $J = 5.0, 1.4$ Hz, 1H), 8.11 (s, 1H), 10.30 (s, 1H); ^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$) δ 119.1 (2C), 125.9, 127.7, 127.9 (2C), 132.7, 133.7, 139.2, 139.9; the three carbon resonances of the hexafluoropropanol unit are not observed in the ^{13}C spectrum of SR3335. The fluorine coupling with these carbons gives multiplets which were difficult to detect even with increased number of scans; FTIR 3362, 3228, 1614, 1519, 1472, 1404, 1341, 1308, 1280, 1257, 1230, 1186, 1146, 1098, 1067, 1027, 963, 946, 928, 832, 821, 730, 708 cm^{-1} ; MS (ES-) $m/z = 404$ (found for $\text{C}_{13}\text{H}_9\text{F}_6\text{NO}_3\text{S}_2\text{H}^+$).

Cell Culture and Cotransfections

HEK293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum at 37 °C under 5% CO_2 . HepG2 cells were maintained and routinely propagated in minimum essential medium supplemented with 10% fetal bovine serum at 37 °C under 5% CO_2 . 24 h prior to transfection, cells were plated in 96-well plates at a density of 15×10^3 cells/well. Transfections were performed using LipofectamineTM 2000 (Invitrogen). 16 h post-transfection, the cells were treated with vehicle or compound. 24 h post-treatment, the luciferase activity was measured using the Dual-GloTM luciferase assay system (Promega). The values indicated represent the means $\pm$ S.E. from four independently transfected wells. The experiments were repeated at least three times. The ROR and reporter constructs have been previously described (5,10).

cDNA Synthesis and Quantitative PCR

Total RNA extraction and cDNA synthesis as well as the QPCR were performed as previously described (19,20).

Radioligand Binding Assay

The radioligand binding assay for ROR α and ROR γ using [^3H]25-hydroxycholesterol has been previously described (5,6,10).

Pharmacokinetic Studies

Plasma levels of SR3335 were evaluated in C57BL/6 mice ($n = 3$ per time point) administered by i.p. injection. After 0.25, 0.5, 1, 2, 4, and 8h blood was taken. Plasma was generated using standard centrifugation techniques, and the plasma and tissues were frozen at -80°C . Plasma and tissues were mixed with acetonitrile (1:5 v/v or 1:5 w/v, respectively), sonicated with a probe tip sonicator, and analyzed for drug levels by liquid chromatography/tandem mass spectrometry. All the procedures were conducted in the Scripps vivarium, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and were approved by the Scripps Florida Institutional Animal Care and Use Committee.

Diet Induced Obesity Model

30 week old Diet induced obese (DIO) C57BL/6 male mice were purchased from Jackson Laboratories that were maintained on a 65% Kcal high-fat diet from weaning. DIO mice were treated twice per day (07:00h and 18:00h) with 15 mg/kg SR3335 or vehicle for 6 days i.p. Pyruvate tolerance test was conducted on day 6 of the treatment. Food was removed from mice in the morning after SR3335 injection, fasted for 6 hours and the pyruvate tolerance test was conducted at 13:00h. Time 0 blood glucose was measured taken from the tail nip and the pyruvate challenge was initiated by injection of 2g/kg of pyruvate i.p. followed by measuring blood glucose at 15, 30 and 60 min following the injection. Blood glucose was measured by one touch ultra glucose-meter.

Acknowledgments

The efforts of P.R.G. and W.R.R. were supported by the National Institutes of Health (NIH) Molecular Library Screening Center Network (MLSCN) grant U54MH074404 (Hugh Rosen, Principal Investigator). This work was also supported by NIH grants DK080201 (T.P.B.) and GM084041 (P.R.G.).

References

1. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. *Nucl Recept Signal*. 2009; 7:e003. [PubMed: 19381306]
2. Solt LA, Griffin PR, Burris TP. Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics. *Current Opinion in Lipidology*. 21:204–211. [PubMed: 20463469]
3. Kallen J, Schlaeppe JM, Bitsch F, Delhon I, Fournier B. Crystal structure of the human ROR alpha ligand binding domain in complex with cholesterol sulfate at 2.2 angstrom. *Journal of Biological Chemistry*. 2004; 279:14033–14038. [PubMed: 14722075]
4. Kallen JA, Schlaeppe JM, Bitsch F, Geisse S, Geiser M, Delhon I, Fournier B. X-ray structure of the hROR alpha LBD at 1.63 angstrom: Structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of ROR alpha. *Structure*. 2002; 10:1697–1707. [PubMed: 12467577]
5. Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordenez RA, Stayrook KR, Zhang X, Novick S, Chalmers MJ, Griffin PR, Burris TP. Modulation of RORalpha and RORgamma activity by 7-oxygenated sterol ligands. *Journal of Biological Chemistry*. 2010; 285:5013–5025. [PubMed: 19965867]
6. Wang Y, Kumar N, Crumbley C, Griffin PR, Burris TP. A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). *Biochim BiophysActa*. 2010; 1801:917–923.
7. Jin LH, Martynowski D, Zheng SY, Wada T, Xie W, Li Y. Structural Basis for Hydroxycholesterols as Natural Ligands of Orphan Nuclear Receptor ROR gamma. *Molecular Endocrinology*. 2010; 24:923–929. [PubMed: 20203100]
8. Lau P, Fitzsimmons RL, Raichur S, Wang SCM, Lechtken A, Muscat GEO. The orphan nuclear receptor, ROR alpha, regulates gene expression that controls lipid metabolism - Staggerer (sg/sg) mice are resistant to diet-induced obesity. *Journal of Biological Chemistry*. 2008; 283:18411–18421. [PubMed: 18441015]
9. Chopra AR, Louet JF, Saha P, An J, DeMayo F, Xu JM, York B, Karpen S, Finegold M, Moore D, Chan L, Newgard CB, O'Malley BW. Absence of the SRC-2 Coactivator Results in a Glycogenopathy Resembling Von Gierke's Disease. *Science*. 2008; 322:1395–1399. [PubMed: 19039140]
10. Kumar N, Solt LA, Konkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordenez R, Burris TP, Griffin PR. The benzenesulfonamide T0901317 is a novel ROR{alpha}/{gamma} Inverse Agonist. *Molecular Pharmacology*. 2010; 77:228–236. [PubMed: 19887649]
11. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li LP, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. *Genes & Development*. 2000; 14:2831–2838. [PubMed: 11090131]
12. Michael LF, Schkeryantz JM, Burris TP. The pharmacology of LXR. *Mini Rev Med Chem*. 2005; 5:729–740. [PubMed: 16101409]
13. Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF, Burris TP. T0901317 is a dual LXR/FXR agonist. *Molecular Genetics and Metabolism*. 2004; 83:184–187. [PubMed: 15464433]
14. Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, Roush WR, Griffin PR, Burris TP. Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORα and RORG. *ACS Chemical Biology*. 2010:null–null.
15. Wang YJ, Solt LA, Burris TP. Regulation of FGF21 Expression and Secretion by Retinoic Acid Receptor-related Orphan Receptor alpha. *Journal of Biological Chemistry*. 2010; 285:15668–15673. [PubMed: 20332535]

16. Delerive P, Chin WW, Suen CS. Identification of Rev-erb alpha as a novel ROR alpha target gene. *Journal of Biological Chemistry*. 2002; 277:35013–35018. [PubMed: 12114512]
17. Raspe E, Mautino G, Duval C, Fontaine C, Duez H, Barbier O, Monte D, Fruchart J, Fruchart JC, Staels B. Transcriptional regulation of human Rev-erb alpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha. *Journal of Biological Chemistry*. 2002; 277:49275–49281. [PubMed: 12377782]
18. Farah BS, Gilbert EE, Sibilio JP. Perhalo ketones. V. Reaction of perhaloacetones with aromatic hydrocarbons. *Journal of Organic Chemistry*. 1965; 30:998–1001.
19. Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, Kamenecka TM, Stayrook KR, Crumley C, Floyd ZE, Gimble JM, Griffin PR, Burris TP. Regulation of Adipogenesis by Natural and Synthetic REV-ERB Ligands. *Endocrinology*. 2010; 151:3015–3025. [PubMed: 20427485]
20. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris LL, Khorasanizadeh S, Burris TP, Rastinejad F. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. *Nat Struct Mol Biol*. 2007; 14:1207–1213. [PubMed: 18037887]

Figure 1.

Identification of a selective ROR α synthetic ligand, SR3335. A) Comparison of the chemical structure of T0901317 to SR3335 and SR1078. B) Scheme illustrating the synthesis of SR3335. C) Competition radioligand binding assay illustrating the ability of SR3335 to displace radiolabeled 25-hydroxycholesterol from ROR α LBD. D) Competition radioligand binding assay illustrating the inability of SR3335 to displace radiolabeled 25-hydroxycholesterol from ROR γ LBD.

Figure 2.

SR3335 is a selective ROR α partial inverse agonist. Cotransfection of HEK293 cells with ROR α , ROR γ or LXR α LBD fused to a GAL4 DNA binding domain and a reporter containing 5 copies of the GAL4 UAS upstream of a luciferase reporter. The effect of T1317 is compared to SR3335 in each assay.

Figure 3. SR3335 suppresses the expression of RORα target genes. A) Treatment of HepG2 cells with 5 μM SR3335 results in suppression of transcription in a full-length RORα, *G6Pase* promoter-luciferase reporter cotransfection assay. *G6Pase* expression was normalized to *cyclophilin*. B) Treatment of HepG2 cells with 5 μM SR3335 results in suppression of *G6Pase* and *PEPCK* mRNA expression. *, indicates $p < 0.05$.

Figure 4.

SR3335 suppresses gluconeogenesis *in vivo*. A) Pharmacokinetic profile SR3335 following a single injection of 10 mg/kg i.p. B) Pyruvate tolerance test in diet induced obese (DIO) mice (C57Bl/6) following 1 week of b.i.d. dosing (i.p.) 15 mg/kg. C) Gene expression in mice following administration of SR3335 as indicated in 4B. Gene expression was normalized to *cyclophilin*. *, indicates $p < 0.05$.